Medicine and Dentistry
Chronic Kidney Disease
100%
Patient
54%
Nephropathy
41%
Analysis
38%
Cardiovascular Disease
36%
Empagliflozin
36%
Kidney
36%
Glomerular Filtration Rate
31%
Diseases
27%
Urinary System
27%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
25%
Acute Kidney Injury
24%
Inpatient
23%
Cardiovascular System
22%
Angiography
21%
Albumin
20%
Creatinine
20%
Kidney Injury
18%
Systematic Review
18%
Dose Response
18%
Biological Marker
18%
Glomerulus
18%
Blood Vessel
18%
Pathologist
18%
Nephrology
18%
Transfer of Learning
18%
Idiopathic Pulmonary Fibrosis
18%
Personalized Medicine
18%
Histopathology
18%
Clinical Research
18%
Development
18%
Collaborative Learning
18%
Translational Research
18%
Maturity
18%
Finerenone
18%
Heart Failure with Preserved Ejection Fraction
18%
Peritoneal Dialysis
18%
Experience
18%
COVID-19
18%
Catheterization
18%
Kidney
18%
Speech-in-Noise Test
11%
Disease Exacerbation
9%
Kidney Function
9%
Diabetes
8%
Cotransporter
7%
Joint
6%
Exercise
6%
Meta-Analysis
5%
Placebo
5%
Albuminuria
5%
Adjustment
5%
Pharmacology, Toxicology and Pharmaceutical Science
Prevalence
18%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
18%
Diabetes Mellitus
18%
Hemodialysis
18%
Cardiovascular Disease
18%
Finerenone
18%
Protein
13%
Interleukin 6
13%
Inflammation
9%
Dose-Response Relationship
9%
End Stage Renal Disease
9%
Cotransporter
5%